Goldman Sachs is still super bullish on bank stocks even after their monster run. Yahoo Finance’s Brian Sozzi shares the details.
Goldman Sachs is still super bullish on bank stocks even after their monster run. Yahoo Finance’s Brian Sozzi shares the details.
Its initial valuation took it close to the price of Goldman Sachs.
The 48-year-old veteran officer has avoided murder charges.
The Democratic chairman of the U.S. House of Representatives Foreign Affairs Committee said on Wednesday he and other lawmakers were concerned about the Biden administration's decision to go ahead with a weapons sale to the United Arab Emirates and would review the transactions. Reuters reported on Tuesday that the Democratic president's administration had told Congress it was proceeding with more than $23 billion in weapons sales https://www.reuters.com/article/idUSL1N2M6319 to the UAE, including advanced F-35 aircraft, armed drones and other equipment. The sale was reached in the last weeks of former Republican President Donald Trump's administration and finalized only about an hour before Biden took office on Jan. 20, and the Democrat's administration had "paused" it in order to conduct a review.
More than 60 former heads of state, including former leaders of Britain and France, and over 100 Nobel Prize winners called on U.S. President Joe Biden to back a waiver of intellectual property rules for COVID-19 vaccines. A waiver would boost vaccine manufacturing and speed up the response to the pandemic in poorer countries which otherwise might have to wait years, they said in a joint letter to Biden sent to news organisations on Wednesday. "President Biden has said that no one is safe until everyone is safe, and now with the G7 ahead there is an unparalleled opportunity to provide the leadership that only the U.S. can provide," said former British Prime Minister Gordon Brown, referring to an upcoming meeting of the world's wealthiest countries.
McConaughey is the latest celebrity to invest in MLS, and he and the club are dreaming big. Will Austin FC deliver?
Prosecutor Jerry Blackwell launched an aggressive cross-examination, attacking a retired pathologist Dr. David Fowler's findings down the line during Derek Chauvin's trial. (Apr. 14)
agilon health, inc. ("agilon health"), which partners with primary care physicians to unlock value-based healthcare delivery, announced the pricing of its initial public offering of 46,600,000 shares of its common stock at a public offering price of $23.00. All of the shares of common stock are being offered by agilon health. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other expenses payable by agilon health, are expected to be approximately $1,072 million. agilon health has granted the underwriters a 30-day option to purchase up to an additional 6,990,000 shares of its common stock at the initial public offering price, less underwriting discounts and commissions.
Patrick Y. Shim is launching 1927 Capital Management, LLC, a family office in partnership with a multi-generation winemaking family based in Southern California.
NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Bellus Health, Inc. (NASDAQ: BLU), Neptune Wellness Solutions, Inc. (NASDAQ: NEPT), Sequential Brands Group, Inc. (NASDAQ: SQBG), and CytoDyn, Inc. (Other OTC: CYDY). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided. Bellus Health, Inc. (NASDAQ: BLU) Class Period: September 5, 2019 to July 5, 2020 Lead Plaintiff Deadline: May 17, 2021 Bellus is a clinical-stage biopharmaceutical company whose lead product is BLU-5937, which is being developed for the treatment of chronic cough (one that lasts over eight weeks) and other afferent hypersensitization-related disorders. Before markets opened on July 6, 2020, defendants revealed the truth about BLU5937’s efficacy. They announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked. Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed. The Phase 2 trial showed a “clinically meaningful and highly statistically significant” effect only on a subset of patients who had high cough counts (around 32 per day), so the Company was planning a Phase 2b trial focused on those patients. On this news, indicating that Bellus had fallen even further behind Merck in developing an FDA-approved treatment for refractory chronic cough, the Company’s stock price plummeted over 75% to close at $2.97 on July 8, 2020. The complaint, filed on March 16, 2021, alleges that defendants’ scheme: (i) deceived the investing public regarding Bellus’s business, operations, drug products, drug product development, competition, and present and future business prospects; (ii) facilitated the Company’s September 2019 public offering (“Offering”); (iii) created artificial demand for the Bellus common shares sold in the Offering; (iv) enabled the Company to receive approximately $70 million in net proceeds from the sale of Bellus common stock in the Offering; and (v) caused Plaintiff and the Class to purchase Bellus publicly traded common stock at artificially inflated prices. For more information on the Bellus Health class action go to: https://bespc.com/cases/BLU Neptune Wellness Solutions, Inc. (NASDAQ: NEPT) Class Period: July 24, 2019 to February 16, 2021 Lead Plaintiff Deadline: May 17, 2021 On May 9, 2019, Neptune announced that it had signed a definitive agreement to acquire the assets of SugarLeaf Labs, LLC and Forest Remedies LLC (collectively, “SugarLeaf”), a registered North Carolina-based commercial hemp company providing extraction services and formulated products (the “SugarLeaf Acquisition”). On July 24, 2019, Neptune announced the closing of the SugarLeaf Acquisition. On February 15, 2021, Neptune announced disappointing financial results for the third quarter of the Company’s fiscal year 2021, missing analyst expectations. Among other results, Neptune reported third quarter revenues of CA$3.32 million and a net loss of CA$73.8 million, down 63.81% and over 1,000% year-over-year, respectively. Neptune attributed the net loss, in part, to a CA$35.6 million impairment of goodwill and a CA$2.1 million impairment of “property, plant and equipment and right-of-use assets related to the acquisition of SugarLeaf in July 2019,” as well as accelerated amortization of CA$13.95 million “also related to the SugarLeaf acquisition.” Additionally, the Company disclosed that its “[g]ross margin declined to a loss of 268.3%,” which included a non-cash CA$7.39 million “write-down of inventory and deposits to reflect their net realizable value.” On this news, Neptune’s stock price fell $0.86 per share, or 30.71%, to close at $1.94 per share on February 16, 2021. Then, on February 17, 2021, prior to the start of the day’s trading session, Neptune issued a press release announcing the termination of an at-the-market offering conducted by the Company, selling 9,570,735 of its common shares and raising approximately $18.6 million in gross proceeds. Just minutes later, Neptune issued a second press release announcing that the Company was conducting a $55 million registered direct offering. On this news, Neptune’s stock price fell another $0.21 per share, or 10.82%, to close at $1.73 per share on February 17, 2021. The complaint, filed on March 16, 2021, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the cost of Neptune’s integration of the assets and operations acquired in the SugarLeaf Acquisition would be larger than the Company had acknowledged, placing significant strain on the Company’s capital reserves; (ii) accordingly, it was reasonably foreseeable that the company would need to conduct additional stock offerings to raise more capital; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times. For more information on the Neptune Wellness class action case go to: https://bespc.com/cases/NEPT Sequential Brands Group, Inc. (NASDAQ: SQBG) Class Period: November 3, 2016 to December 11, 2020 Lead Plaintiff Deadline: May 17, 2021On February 28, 2018, Sequential Brands Group issued a press released entitled “Sequential Brands Group Announces Fourth Quarter and Full Year 2017 Financial Results” which belatedly announced the goodwill adjustment. On this news, Sequential Brands Group’s stock price fell $6.80 per share, or 8%, to close at $76.00 per share on February 28, 2018. Then on December 11, 2020, the SEC filed a Complaint alleging that the Company failed “to take into consideration clear, objective evidence of likely goodwill impairment, which avoided and delayed a material write down to goodwill in the fourth quarter of 2016 and the first three quarters of 2017 (the ‘Relevant Period’).” On this news, Sequential Brands Group’s stock price fell $2.03 per share, or 11%, to close at $16.20 per share on December 11, 2020. The complaint, filed on March 16, 2021, alleges that throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (1) in late 2016, the Company knew or should have known that its goodwill was likely impaired; (2) the Company avoided and delayed the material write down to goodwill in late 2016 through 2017; (3) the Company understated its operating expenses and net loss and also materially overstated its income from operations, goodwill, and assets from late 2016 through 2017; (4) the Company’s internal controls were deficient; (5) the Company has failed to restate, correct, or disclose relevant improprieties, deceptive conduct, misstatements, omissions, and control violations; (6) as a result of the foregoing, the Company was at greater risk of regulatory scrutiny and enforcement; and (7) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages. For more information on the Sequential Brands class action go to: https://bespc.com/cases/SQBG CytoDyn, Inc. (Other OTC: CYDY) Class Period: March 27, 2020 to March 9, 2021 Lead Plaintiff Deadline: May 17, 2021 CytoDyn is focused on the development and commercialization of a drug named “Leronlimab” which has long been promoted as a potential therapy for HIV patients. Since the beginning of the global COVID-19 pandemic, however, CytoDyn has begun to aggressively tout Leronlimab as a treatment for COVID-19. Beginning on March 5, 2021 CytoDyn began issuing press releases that described the results of Phase IIb/III testing data. In these releases, CytoDyn disclosed that the primary endpoint for the Leronlimab study (all-cause mortality at Day 28) was not statistically significant. After closing at $4.05 on March 5, 2021, CytoDyn shares dropped over 28% to close at $2.91 on March 8, 2021. On March 9, 2021, CytoDyn shares dropped an additional 19% to close at $2.35. The complaint, filed on March 17, 2021, alleges that defendants violated provisions of the Exchange Act by making false and misleading statements concerning Leronlimab being used as a treatment for Covid-19. For more information on the CytoDyn class action go to: https://bespc.com/cases/CYDY About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes. Contact Information:Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Melissa Fortunato, Esq.Marion Passmore, Esq.(212) firstname.lastname@example.org
R-CALF USA, et al. v. U.S. Department of Agriculture, et al.Washington, D.C., April 14, 2021 (GLOBE NEWSWIRE) -- Influenced by a lawsuit brought by the New Civil Liberties Alliance on behalf of America’s livestock producers against the U.S. Department of Agriculture (USDA) and its subagency, the Animal and Plant Health Inspection Service (APHIS), the Wyoming Legislature recently passed HB0229, allowing cattle and bison producers in the state to use a variety of identification methods for their livestock. In July 2020, USDA sent shockwaves through the livestock industry when it published a notice in the Federal Register proposing to define an “official eartag” under the 2013 Final Rule governing animal identification and traceability as being limited to radio frequency identification (RFID) eartags. The move prohibited the use of low-cost and popular traditional eartags. USDA’s recent activity followed its decision in April 2019 to issue a two-page factsheet or “guidance document” mandating livestock producers to begin using RFID eartags in 2023. NCLA successfully challenged the legality of USDA’s factsheet, thereby forcing the agency to withdraw it in October 2019. Under HB0229, livestock producers in Wyoming can continue using any form of identification referenced in the 2013 Final Rule, including brands, tattoos, metal or plastic eartags, back tags, and group identification numbers. NCLA, a nonpartisan, nonprofit civil rights group, represents the trade association Ranchers Cattlemen Action Legal Fund United Stockgrowers of America (R-CALF USA), and four ranchers—Tracy and Donna Hunt from Wyoming, and Kenny and Roxy Fox from South Dakota—in R-CALF USA, et al. v. U.S. Department of Agriculture, et al. The lawsuit currently pending before the U.S. District Court for the District of Wyoming argues that USDA and APHIS failed to comply with the Federal Advisory Committee Act’s (FACA) statutory requirements in establishing and using two advisory committees to gather information necessary to implement the RFID eartag mandate. If NCLA’s FACA lawsuit succeeds, USDA will not be able to use any of the recommendations or information obtained from the unlawful advisory committees in proposing a new RFID rule. The passage of HB0229 is the second victory for livestock producers resulting from NCLA’s aggressive legal challenges against administrative agencies that “legislate by guidance,” thereby avoiding the strictures of the Administrative Procedure Act (APA) while imposing ever increasing mandates and requirements on the regulated public. USDA and APHIS announced last month that they will go through a full rule-making process pursuant to APA to make any changes to the 2013 Final Rule governing animal identification and traceability. These agencies have again been forced to abandon their attempt to replace the 2013 Final Rule with guidance, which has been at the root of NCLA’s legal objection. NCLA released the following statements: “We are pleased that the Wyoming legislators understand the importance of protecting our livestock producers’ right to choose which form of identification best works for their operations. USDA and APHIS have been relentless in their efforts to force our producers to convert to a costly and complicated RFID eartag program. The passage of HB0229 is now one more roadblock to those efforts. We hope other states will follow suit.”— Harriet Hageman, Senior Litigation Counsel, NCLA “We applaud the State of Wyoming for protecting the private property rights of Wyoming ranchers. The law provides that ranchers everywhere can choose to identify their property—their livestock—in the manner that best suits their operations. USDA tried unlawfully to take that choice away. The State of Wyoming has now ensured it won’t happen again.”— Bill Bullard, CEO, R-CALF USA For more information visit the case page here. ABOUT NCLA NCLA is a nonpartisan, nonprofit civil rights group founded by prominent legal scholar Philip Hamburger to protect constitutional freedoms from violations by the Administrative State. NCLA’s public-interest litigation and other pro bono advocacy strive to tame the unlawful power of state and federal agencies and to foster a new civil liberties movement that will help restore Americans’ fundamental rights. ### CONTACT: Judy Pino, Communications Director New Civil Liberties Alliance 202-869-5218 email@example.com
Television Univision, a newly formed Spanish media venture, will launch its planned streaming platform in the United States and Mexico next year before expanding elsewhere in Latin America and in Europe, its chief executive told Reuters on Wednesday. The service, which will take on established rivals including Netflix Inc and Disney Plus, will be a product of a move to combine the content of Mexican broadcaster Grupo Televisa and U.S. peer Univision, announced on Tuesday. Televisa shares surged by as much as a third before closing with a gain of 22.8% on the day, as investors bet on the growth potential of the venture.
The shocking site was captured by someone's front door security camera. Source: Daily Star via Twitter
GameStop Corp Chief Executive Officer George Sherman has forfeited more than 587,000 shares as he failed to meet his performance targets, according to a regulatory filing on Wednesday. GameStop is currently looking for a new CEO to replace Sherman as it pivots from a brick-and-mortar video game retailer to an e-commerce firm, Reuters reported on Monday, citing three sources. Chris Homeister, GameStop's chief merchandising officer, forfeited more than 119,000 shares for failing to meet targets, another filing showed.
Jurgen Klopp rued Liverpool not taking “massive chances” against Real Madrid as the Reds crashed out of the Uefa Champions League. Liverpool headed into Wednesday night’s quarter-final second leg trailing 3-1 on aggregate following a tough defeat in Madrid last time out, and started well at Anfield.
MONTERREY, Mexico, April 14, 2021 (GLOBE NEWSWIRE) -- Fomento Económico Mexicano, S.A.B. de C.V. ("FEMSA") (NYSE: FMX; BMV: FEMSAUBD, FEMSAUB) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2020 with the U.S. Securities and Exchange Commission (SEC) and its annual report, for the same period, with the Comisión Nacional Bancaria y de Valores (Mexican Banking and Securities Commission) and the Bolsa Mexicana de Valores (Mexican Stock Exchange). These reports are available on FEMSA's investor relations website at http://ir.femsa.com. Shareholders may receive a hard copy of the report, which includes FEMSA’s audited financial statements, free of charge through the contact listed below. Contact: firstname.lastname@example.org(52) 818-328-6167 About FEMSAFEMSA is a company that creates economic and social value through companies and institutions and strives to be the best employer and neighbor to the communities in which it operates. It participates in the retail industry through FEMSA Comercio, comprising a Proximity Division operating OXXO, a small-format store chain, a Health Division, which includes drugstores and related activities, and a Fuel Division, which operates the OXXO GAS chain of retail service stations. In the beverage industry, it participates through Coca-Cola FEMSA, a public bottler of Coca-Cola products; and in the beer industry, as a shareholder of HEINEKEN, a brewer with operations in over 70 countries. Additionally, through its Strategic Businesses unit, it provides logistics, point-of-sale refrigeration solutions and plastics solutions to FEMSA's business units and third-party clients. FEMSA also participates in the specialized distribution industry in the United States. Through its business units, FEMSA has more than 320,000 employees in 13 countries. FEMSA is a member of the Dow Jones Sustainability MILA Pacific Alliance, the FTSE4Good Emerging Index and the Mexican Stock Exchange Sustainability Index, among other indexes that evaluate its sustainability performance. CONTACT: Media Contact (52) 555-249-6843 email@example.com www.femsa.com Investor Contact (52) 818-328-6167 firstname.lastname@example.org www.femsa.com/inversionista
The manager of a Waco car dealer offered Baylor coach Scott Drew the use of a custom Jeep. Then he made a comment that caused Baylor to decline the offer.
Pico, a New York startup that helps online creators and media companies make money and manage their customer data, announced today that it has launched an upgraded platform and raised $6.5 million in new funding. In a statement, the startup's co-founder and CEO Nick Chen said Pico helps creators with their two biggest problems — "how to make money more easily and how to get to know your audience better" — while also giving them control over their two most important assets, namely "your brand and the relationship to your audience."
Bill also promotes food allergy research; Moves to White House to be signed into law Congress Passes FASTER Act. Sesame to be declared major food allergen. It's another huge AAFA Advocacy Win! Bill moves to the White House to be signed into law. Washington, D.C., April 14, 2021 (GLOBE NEWSWIRE) -- Today the House passed Act, S. 578/H.R.1202, otherwise known as the FASTER Act. It declares sesame the 9th major food allergen recognized by law in the United States. This means food manufacturers will have to list sesame as an allergen on food labels. Manufacturers will have until January 1, 2023 to comply. The new addition to the top allergen list is a major update the Asthma and Allergy Foundation of America (AAFA) has been leading the fight on for years. FASTER is an acronym for Food Allergy Safety, Treatment, and Research Act. The bill also strengthens focus on food allergy research which will help improve resources for people living with food allergies. Because the bill has already cleared the Senate, it now heads to the president’s desk to be signed into law. “This is terrific progress for our food allergy community. Adding sesame to the major allergen list is a much-needed change and a significant part of this legislation. This has been a top priority for AAFA and our Kids With Food Allergies division since 2008 and since we joined forces with the Center for Science in the Public Interest (CSPI) in 2017 to start this campaign. We’re grateful to our counterparts at Food Allergy Research & Education (FARE) for spearheading efforts on the FASTER Act and supporting our recommendation to add sesame to this legislation,” said Kenneth Mendez, CEO and president of AAFA. “AAFA’s thrilled we were able to bring a variety of key food allergy groups together to support sesame labeling as we worked dual tracks with both Congress and the Food and Drug Administration (FDA) to add sesame to the major allergen list.” More than 32 million Americans have food allergies. Sesame is a serious allergy for over one million people in the United States. Proper labeling makes the difference between what can be safe to consume, or pose a serious health risk. “It takes massive effort to make massive change,” said Jenna Riemenschneider, AAFA’s director of advocacy. “This is the result of years of hard work and the power of our amazing food allergy community. We’re extremely grateful to the thousands of AAFA community members who’ve joined us by using their voices to get the FASTER Act passed. From the over 500 individual reports we collected and submitted to the FDA on allergic reactions to sesame, to the over 3,000 emails sent in the past couple weeks by our AAFA/KFA community to encourage their Congressional leadership to support this bill, there was no letting up until we got the job done. This life-changing legislation expands public health knowledge of all food allergies and makes food labels safer for people with sesame allergy.” AAFA looks forward to seeing the FASTER Act signed into law and implemented. This victory fuels the foundation’s continued work with Congress and the FDA to advance even further protections for people living with food allergies. AAFA thanks Representatives Doris Matsui (D-CA) and Steny Hoyer (D-MD) for their consistently strong leadership on this bill. A special round of thanks also goes to Senators Tim Scott (R-SC) and Chris Murphy (D-CT) for their work in moving the bill through the Senate. To learn more about the FASTER Act and what it means for you, go to: kidswithfoodallergies.org/faster-act Ongoing advocacy efforts through AAFA’s Kids With Food Allergies division can be supported via secure donation here: Support Kids With Food Allergies. To get involved, register with AAFA’s patient advocacy communities by heading to aafa.org/join and kidswithfoodallergies.org/join. ## About AAFA Founded in 1953, AAFA is the oldest and largest non-profit patient organization dedicated to saving lives and reducing the burden of disease for people with asthma, allergies and related conditions through research, education, advocacy and support. AAFA offers extensive support for individuals and families affected by asthma and allergic diseases, such as food allergies and atopic dermatitis (eczema). Through its online patient support communities, network of local chapters and affiliated support groups, AAFA empowers patients and their families by providing practical, evidence-based information and community programs and services. AAFA is the only asthma and allergy patient advocacy group that is certified to meet the standards of excellence set by the National Health Council. For more information, visit www.aafa.org. Attachment faster-act-passes-congress-TW CONTACT: Kafi Drexel Brown, Public Relations Director Asthma and Allergy Foundation of America 202.974.1223 email@example.com
Northland Power has made its first foray into Spain's fast-growing renewable energy generation market with a deal to buy a portfolio of wind farms and solar parks, the Canadian company said on Wednesday. A wave of global targets to cut carbon emissions are stoking investor interest in renewable energy businesses, and Spain's sunny plains, windy hillsides and political enthusiasm for the sector have made it a focus for the market in Europe. Northland Power said in a statement it will pay 345 million euros ($413.3 million) in cash for the assets, which are located across Spain, and take on 716 million euros in debt.
(Bloomberg) -- Argentina’s inflation accelerated last month at the fastest pace since President Alberto Fernandez took office in late 2019, prompting the government to tighten its unorthodox controls over companies.Consumer prices rose 4.2% in March from February, according to the median forecast of economists surveyed by Bloomberg ahead of Thursday’s release. Economy Minister Martin Guzman said Wednesday that inflation should cool in April after reaching its peak for the year last month.Read More: Argentinian Policy, Growth Limbo Until IMF Deal StruckDouble-digit inflation has been a persistent problem for recent administrations in Argentina. To combat it, Fernandez’s government has relied on unorthodox tools including price caps and agreements, rejecting traditional monetary options used by most countries.The recent spike, with the inflation rate running at about 40% annually, threatens to derail Argentina’s fragile economic recovery six months before key midterm elections. On Wednesday, the government ordered stricter enforcement of price controls and said it would hire as many as 500 inspectors to ensure businesses are complying with regulations.Guzman asked for “more cooperation” by companies to try to reach the government’s 29% annual inflation target for the end of 2021. Economists say the rate accelerated to almost 42% in March.The clampdown on prices has also led to an uneasy relationship between Fernandez’s government and businesses. U.S. companies recently asked his administration to ease up on price controls, calling the regulatory environment “hostile, restrictive and unpredictable.”Read More: Inflation Will Keep Accelerating in Latin America, Goldman SaysArgentina’s statistics agency INDEC is set to release March’s inflation rate at 4 p.m. on Thursday.For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.